Hussman Strategic Advisors Inc. Purchases 10,500 Shares of Halozyme Therapeutics, Inc. $HALO

Hussman Strategic Advisors Inc. grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 84,000 shares of the biopharmaceutical company’s stock after acquiring an additional 10,500 shares during the quarter. Halozyme Therapeutics makes up about 1.0% of Hussman Strategic Advisors Inc.’s holdings, making the stock its 14th biggest holding. Hussman Strategic Advisors Inc.’s holdings in Halozyme Therapeutics were worth $4,370,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Penserra Capital Management LLC bought a new position in shares of Halozyme Therapeutics during the first quarter valued at about $125,000. Redhawk Wealth Advisors Inc. lifted its stake in shares of Halozyme Therapeutics by 14.8% in the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock valued at $1,947,000 after acquiring an additional 4,827 shares during the last quarter. Intech Investment Management LLC boosted its holdings in Halozyme Therapeutics by 9.9% during the 1st quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock valued at $9,776,000 after acquiring an additional 13,789 shares during the period. Focus Partners Wealth boosted its holdings in Halozyme Therapeutics by 57.8% during the 1st quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock valued at $7,709,000 after acquiring an additional 44,260 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its position in Halozyme Therapeutics by 78.0% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 102,000 shares of the biopharmaceutical company’s stock worth $5,305,000 after acquiring an additional 44,700 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HALO has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Benchmark lifted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, October 21st. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and an average target price of $73.11.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $66.20 on Tuesday. The firm has a market capitalization of $7.74 billion, a price-to-earnings ratio of 15.15, a PEG ratio of 0.35 and a beta of 1.16. The stock has a fifty day moving average of $71.04 and a 200 day moving average of $62.61. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $79.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same period in the previous year, the firm earned $0.91 EPS. The company’s quarterly revenue was up 40.8% compared to the same quarter last year. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00. Following the sale, the director directly owned 44,952 shares of the company’s stock, valued at approximately $3,382,188.48. The trade was a 4.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Nicole Labrosse sold 2,227 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the transaction, the chief financial officer owned 22,079 shares in the company, valued at $1,721,058.05. This trade represents a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 108,227 shares of company stock valued at $7,779,595. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.